Patents by Inventor Wenwen QI

Wenwen QI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical preparation and use thereof
    Patent number: 11337972
    Abstract: A pharmaceutical preparation includes a first active component, a second active component and pharmaceutically acceptable excipients. The first active component is at least one selected from the group consisting of a neutral endopeptidase inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The second active component is at least one selected from the group consisting of a compound represented by the following formula (I) or a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The pharmaceutically acceptable excipients include one or more disintegrants and/or one or more fillers.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: May 24, 2022
    Assignees: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD., WUHAN QR PHARMACEUTICALS CO., LTD., WUHAN ZY PHARMACEUTICALS CO., LTD.
    Inventors: Xiaojing Hu, Lina Qian, Zhichao Zhang, Yuanping Wang, Yongkai Chen, Wei Feng, Wenwen Qi, Chaodong Wang
  • PHARMACEUTICAL PREPARATION AND USE THEREOF
    Publication number: 20210052579
    Abstract: A pharmaceutical preparation includes a first active component, a second active component and pharmaceutically acceptable excipients. The first active component is at least one selected from the group consisting of a neutral endopeptidase inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The second active component is at least one selected from the group consisting of a compound represented by the following formula (I) or a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The pharmaceutically acceptable excipients include one or more disintegrants and/or one or more fillers.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 25, 2021
    Applicants: Wuhan ll Science and Technology Development Co., Ltd., Wuhan qr Pharmaceuticals Co., Ltd., Wuhan zy Pharmaceuticals Co., Ltd.
    Inventors: Xiaojing HU, Lina QIAN, Zhichao ZHANG, Yuanping WANG, Yongkai CHEN, Wei FENG, Wenwen QI, Chaodong WANG